Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B infection has a presentation and clinical course that is divergent from that of HBeAg-positive infection. The former usually presents with lower viral levels but faster progression to liver disease. We sought to better understand the balance between replication and the immune response against hepatitis B virus (HBV).
are HBeAg negative [3] , because they are infected with HBV variants that are unable to produce high amounts of the excreted protein that bears the HBe epitope. These HBV variants are rather uncommon in North America and Northern Europe, but the vast majority of patients with CHB in Southern Europe and Africa is infected with variants that express little or no HBeAg, and prevalence of HBeAg-negative CHB seems to be increasing worldwide [3] [4] [5] .
Infection with HBeAg-negative hepatitis B variants is associated with lower serum viral levels [6] [7] [8] , higher intrahepatic necroinflammatory lesions, and more severe progression of disease, with frequent development of cirrhosis and/or hepatocellular carcinoma [9, 10] than is infection with HBeAg-positive strains [6, 11] . Taken together, these observations may indicate a stronger immune response against HBeAg-negative infection. Consistent with this, even though the function of the HBe protein is not clear, it has been suggested that it serves to downmodulate the immune response [12, 13] . In addition, HBeAgnegative HBV patients represent a patient pool that is more difficult to treat due to lower off-treatment sustained responses [7, 14, 15] .
Modeling of different viral infections and their treatment has given insight into aspects of viral evolution, pathogenesis, and the mechanisms of antiviral drug action [16] [17] [18] [19] [20] . Such analyses of HBeAg-positive HBV infection showed that this virus has a short half-life in plasma and rapid viral production. We and others have calculated that the daily production of HBV in HBeAg-positive infection is in excess of 10 11 virions and that infected cell life span is variable but can be as short as 2 days [21, 22] . A few studies have also analyzed the effect of drug therapy on the kinetics of HBeAg-negative viral infection [23, 24] . The results from these studies suggest that viral clearance may be even faster in the setting of HBeAg-negative infection.
Here we analyze the dynamics of HBeAg-negative infection under a variety of drug treatments and conduct an exhaustive meta-analysis of published results concerning HBV dynamics.
Our goal was to understand the respective roles played by viral production and the immune response in HBeAg-negative infection and compare them with HBeAg-positive infection. [25] . All had well-compensated active liver disease, and liver biopsy showed a modified Ishak histological activity index of at least 6, with a fibrosis score of at least 1. The patients had no coinfections with hepatitis delta virus, hepatitis C virus, or human immunodeficiency virus. The study was approved by the Ethical Committee of the Scientific Council of Papageorgiou General Hospital. All patients gave informed consent for the kinetic study.
PATIENTS AND METHODS

Patients
Therapy. The therapy protocols used in this study were accepted clinical practice or investigational protocols for drugs being developed at the time of patient enrollment. Twelve patients received standard interferon a (IFN-a) 2a monotherapy, 4.5 MU 3 times a week (IFN group), 10 received lamivudine monotherapy, 100 mg daily (LAM group), 10 received a combination of both standard IFN-a2a and lamivudine at the same doses (IFN+LAM group), 6 received pegylated IFN-a2a monotherapy, 180 mg weekly (PEG group), 7 received a combination of pegylated IFN-a2a and lamivudine (PEG+LAM group), and 11 received a combination of adefovir dipivoxil, 10 mg daily, and lamivudine, 100 mg daily (ADV+LAM group) ( Table 1) . Of this last group, 6 were patients whose first treatment regimen Table 2 ), and the best-fit regression line is also shown.
had failed and were retreated with this second protocol; they were noted with the suffix "b" after their number (eg, P11b). Treatment was maintained in all included patients for 48 weeks, and all patients were followed for at least 12 more months. However, for the majority of the patients (29 patients), biochemical response (normal alanine aminotransferase level), virological response (undetectable HBV DNA), and complete response (HBsAg loss) were assayed at 24 months posttreatment.
We initiated treatment in 56 patients (6 patients were treated twice). However, for 7 patients there was not enough followup to analyze the data, either because the viral load went below detection too quickly, usually within the first 2 days (4 patients: P24b, P34, P36, and P49) or circumstances precluded sampling the patient at the protocol times (3 patients: P7, P33, and P39). We do not consider these patients further. Thus, in all, we analyzed data from 49 patients ( Table 1) .
HBV DNA quantification. HBV DNA was quantified by an in-house real-time polymerase chain reaction assay with lower limit of detection of 350 IU/mL using an international quantification standard (Optiqual HBV DNA Controls, AcroMetrix). This test is linear up to 10 9 IU/mL, and samples with 19 logs were diluted 1/100 and retested. The patients were sequentially included into the different treatment groups according to availability of the drugs and treatment guidelines. Therefore, the sampling protocols differed slightly among the groups. All patients from the PEG+LAM and PEG groups and 7 patients from the LAM group had HBV DNA measurements at treatment commencement, then at 8 h; 1, 2, 4, 5, and 7 days; and 2, 3, 4, 5, 6, 8, 12, 18, 24, and 30 weeks after initiation of treatment. In the ADV+LAM group, the schedule was almost identical except that no samples were obtained at 8 h. Measurements were obtained more frequently in the 3 remaining patients from the LAM group and in all patients from the IFN or IFN+LAM groups: 0 h, every 6 h up to and including 48 h, and every 12 h through day 5. Measurements were then obtained every second day through day 15, every third day from days 15 through 30, and then at the end of every month through 12 months after therapy initiation. For most patients, samples were obtained 4 and 2 weeks before treatment to define baseline viral load as the average of these and the time zero sample. Mathematical model. Analysis of the dynamics of HBV under treatment was based on the standard model of viral infection [21] :
where T is the number of target cells, I is the number of productively infected cells, and V is the virion concentration. The parameter s denotes the rate at which target cells are produced and the constant d represents their death rate. Target cells become infected at rate b per uninfected cell per virion, and infected cells die at rate d. The production and release of hepatitis B virions by infected cells occurs at an average rate of p 
v where , , and l p 0.
This solution includes a delay, t, between treatment administration and its effect on viral level, and is valid for all times t after this delay. For , , the initial viral level. This t ! t V(t) p V 0 modeling approach corresponds to that used in many viral dynamics studies [19, 21, 26, 27 ] to which we would like to compare our results.
Data fitting. Individual nonlinear least-squares fits were performed using a Levenberg-Marquardt algorithm. To maintain the validity of the assumption that the number of target cells remains constant, the fits were limited to data collected during the first 30 days. Because previous work indicates that h has very little influence on the data fits, we fixed it at 0.5 for all patients [21, 28] . Other parameters were free, with the exception of t for patients 12 and 32, for whom we could not find a stable value and this delay was fixed ( Table 1) . The virion and infected cell half-lives were calculated from the estimated values of c and d as and , respectively. ln (2)/c ln (2)/d Meta-analysis of published data. A meta-analysis was conducted to compare viral kinetics in HBeAg-positive and HBeAgnegative patients. On 23 October 2008, a Pubmed search was performed with the keywords "dynamics HBV," "model kinetics HBV," "mathematical model HBV," and "dynamics HBV treatment," and the same expressions with "HBV" replaced with "hepatitis B", for papers in English without restriction of dates. Of the over 140 papers retrieved, 17 papers included viral dynamics analyses similar to the one conducted in this paper, but only 7 provided individual patient's parameter estimates that could be used for our analyses. We also analyzed by forest plots [29] the data in all studies that provided mean and standard deviations for the kinetic parameters of HBeAg-positive and HBeAg-negative individuals (10 studies).
Statistical analyses. We used parametric tests whenever the necessary assumptions were met. We checked these assumptions by analyzing normality of the data and/or the residuals of the fits as appropriate. When necessary, transformations of the data (eg, taking the square root or the logarithm) were used to comply with homoscedasticity and normality of residuals. Results are presented as mean ‫ע‬ standard error of the mean, unless otherwise specified. All statistics were performed using S-Plus 2000 software (MathSoft Inc) and R software (R Project for Statistical Computing, Vienna, Austria).
RESULTS
Baseline characteristics and outcome of treatment. Pretreatment HBV DNA levels, at
, ranged from to 3 t p 0 2.8 ϫ 10 IU/mL (Table 1) , with a geometric mean of 9 1.0 ϫ 10 6.5 ‫ע‬ log 10 IU/mL. There were no significant differences in av-0.2 erage pretreatment HBV DNA levels across treatment groups ( ) . P p .39 HBV DNA levels went below the detection limit of 350 IU/ mL at least once during treatment in 36 patients, mostly within the first 24 weeks. Relapses in viral load and biochemical parameters were observed within 12 months of stopping therapy, except for patient 5 (sustained responder for over 2 years) and patient 41 (seroconverted to anti-HBs antibodies at 8 months posttherapy). Baseline HBV DNA level was the most important factor predicting the patient's early response to treatment. Patients with undetectable HBV DNA at 8 or 12 weeks of treatment had significantly lower baseline HBV DNA levels, inde- Table 2 , for free virions and infected cells, respectively. Panels c and d restrict the data to those studies with similar treatments, frequent early sampling, and models (see text). The bottom and top of the box represents the 25th and 75th percentile of the data, respectively; the whiskers represent 1.5 times the interquartile range and give an idea of the range of values in the data; and the symbol inside the box represents the median of the data. pendent of treatment schedule ( ), as reported else-P p .008 where [30] .
HBV decay patterns. In most patients, HBV DNA levels showed a biphasic decay after treatment initiation (Figure 1 ). Four patients (P26, P27, P38, and P43) had only a single decay phase over the first 30 days. The biphasic decay was characterized by an early, rapid decline in HBV, followed by a slower second-phase decrease.
The average drop in HBV DNA level after 48 h of treatment was 0.83 log 10 IU/mL. This decrease over the first 48 h differed significantly by treatment regimen: average HBV declines were 1.30, 1.01, 1.05, 0.57, 0.48, and 0.45 log 10 IU/mL for patients in the LAM, ADV+LAM, IFN+LAM, PEG+LAM, PEG alone, and IFN alone regimens, respectively ( ). These differ-P ! .001 ences became less pronounced with time, and, at 1 month, all (except the IFN) groups had similar viral declines (between Ϫ2.6 and Ϫ3.1 log 10 , ); the IFN monotherapy group P p .31 had a Ϫ1.5 log 10 decline.
Kinetic parameters. In Figure 1 we show representative fits of the model to the data (see Figure 2) . We could not fit the data of those patients for whom therapy induced no or minimal decay (4 patients: P3, P10, P17, and P46), nonresponders, or for whom only 1 phase of decay was observed (4 patients: P26, P27, P38, and P43). The reasons why some patients present these nonbiphasic patterns are not known, but this is often the case for large viral dynamics data sets.
In general, the estimated parameters (Table 1) were not significantly different among the treatment groups. Overall, the mean ‫ע‬ standard error values for the clearance rate of virions (c) and infected cells (d) were and day Ϫ1 , 1.9 ‫ע‬ 0.4 0.10 ‫ע‬ 0.01 respectively. The corresponding half-lives were h for 16.6 ‫ע‬ 1.9 virions and days for infected cells. The average ef-13.4 ‫ע‬ 2.9 fectiveness (e) of all treatment regimens was , and 0.90 ‫ע‬ 0.02 the average delay (t) between treatment initiation and its effect on viral load was h. However, protocols including 9.6 ‫ע‬ 2.4 pegylated IFN-a2a had a significantly larger delay than did other treatments (20.6 vs 9.1 h;
). P p .002 Baseline HBV DNA level correlated negatively with infected cell half-life ( ; ) (Figure 3, filled circles) , sugr p Ϫ0.55 P ! .001 gesting that, in HBeAg-negative infection, patients with higher baseline viral levels clear infected cells faster.
Meta-analysis comparison with other viral kinetic studies. To compare our results with other available viral dynamics studies of HBV treatment in both HBeAg-positive and HBeAg-neg- [26] reported the 2 treatment arms separately, as indicated in the first 2 rows of the graphs. The diamonds indicate the point estimates for the studies in each group, with the width indicating the 95% confidence interval. Each study is indicated by its mean (square) and confidence interval (horizontal line). The size of the square shows the contribution of that study to the summary mean, and this depends on study size and uncertainty.
ative patients, a Pubmed search was conducted (see Patients and Methods). Table 2 presents a summary of the 7 published studies that were used in our meta-analysis. Those papers, together with the present study, have information on 79 HBeAg-positive patients and 100 HBeAg-negative patients treated with a variety of different antiviral treatment regimens. For each patient, the halflife of free virions and the half-life of infected cells were obtained. The information on baseline viral level was more difficult to use because different HBV DNA assays were used in the 7 studies (Table 2 ). In 4 of the studies that did not report levels of IU/ mL, we converted baseline HBV DNA levels according to the conversion factors provided by Shyamala et al [31] . The other 2 studies [21, 32] either did not report individual baseline HBV DNA levels or used in-house assays, for which the conversion factor was not reported. Importantly, the estimates for the halflives of free virions and infected cells are not impacted by the specific assay and/or units used in a given study.
As expected, baseline HBV DNA levels were significantly lower in HBeAg-negative than in HBeAg-positive patients: means versus log 10 IU/mL, respectively ( ). 6.3 ‫ע‬ 0.1 7.9 ‫ע‬ 0.1 P ! .001 The range in baseline viral levels in HBeAg-negative (range, 3.4-9.5 log 10 IU/mL) was 100-fold larger than that in HBeAg-positive infection (range, 5.3-9.7 log 10 IU/mL), mostly at the lower end.
We next compared the viral kinetics parameters. The halflife of free virions was significantly shorter in HBeAg-negative infection than in HBeAg-positive infection (mean, 13.1 ‫ע‬ 1.1 h vs h; ) ( Figure 4A ), and the same was true 25.2 ‫ע‬ 1.7 P ! .001 for the half-life of infected cells (mean, days vs 12.1 ‫ע‬ 1.4 days; ) ( Figure 4B ). To extend these results, 16.0 ‫ע‬ 1.7 P ! .001 we included 3 other studies (for a total of 10 studies) that reported means and standard deviations for the kinetic parameters in HBeAg-positive and HBeAg-negative infection and summarized the entire data set as forest plots in Figure 5 . The diamonds, which represent the overall parameter estimates in HBeAg-positive and HBeAg-negative subjects, do not overlap, lending support to our results above.
It could be argued that the different treatments, sampling schedules (Table 2) , and modeling approaches affect the interpretation of these estimates [23] , especially because none of the studies in HBeAg-positive infection used IFN or PEG-IFN. Thus, we compared the half-lives of virions and infected cells only in studies with nucleoside or nucleotide analog RTI. The results were consistent: the half-lives of virions ( ) and P ! .001 infected cells ( ) are faster in HBeAg-negative infection. P p .013 To make this comparison even more strict, we repeated this last analysis with data from 2 studies conducted by us, with similar sampling and, crucially, the same fitting procedure (present work; [33] ) ( Figure 4C and 4D) . The conclusions were similar for both the free virion half-life ( ) and the in-P ! .001 fected cell half-life ( ). P p .029 Analyzing all the patients infected with HBeAg-negative HBV ( ) confirmed our results that the half-life of inn p 81 fected cells is negatively correlated with baseline HBV DNA level ( ; ) (Figure 3 ). This was not the case in r p Ϫ0.51 P ! .001 the HBeAg-positive HBV patients ( ; ). Imporn p 48 P p .73 tantly, if we restrict the analysis of HBeAg-negative infection to those patients who have baseline viral load in a similar range to the HBeAg-positive cohort, we find that the negative correlation still holds ( ; ; ). Thus, this r p Ϫ0.45 P ! .001 n p 63 relationship between infected cell half-life and baseline viral load is a characteristic of HBeAg-negative infection and not an artifact of different viral load levels in these patients. We then compared pretreatment steady state viral production, calculated by multiplying the free virion clearance rate by baseline viral load. There was a significantly larger virion production in HBeAg-positive infection than that in HBeAg-negative infection ( vs log 10 IU/mL/day; ), con-7.8 ‫ע‬ 0.15 6.4 ‫ע‬ 0.15 P ! .001 sistent with the higher viral load at baseline observed in the former case.
DISCUSSION
In this study we have analyzed the viral dynamics in HBe antigen-negative hepatitis B virus infection, based on patient response to different antiviral treatment protocols involving IFNa and/or nucleoside or nucleotide analogs. By using a standard model [19] of viral infection, we were able to estimate viral clearance, infected cell loss rate, and the effectiveness at stopping viral production of different treatment protocols. Overall, we did not detect significant differences in viral kinetic parameters among the different study groups. However, we cannot make definitive conclusions about the differences in treatment regimens, because the inclusion in each arm was not random (see Patients and Methods).
We also conducted a meta-analysis to compare our results to those of all previous viral kinetic studies that included data for individual patients (Table 2) . We found a significantly faster viral clearance rate (and thus shorter viral half-life) for HBeAgnegative infection than for HBeAg-positive infection. The viral half-life in HBeAg-positive infection was ∼25 h, whereas in HBeAg-negative infection it was ∼13 h. This observation may be related to the lower viral levels at baseline in the latter group of patients, because it was reported that faster virion clearance correlate with lower baseline viral loads [34, 35] . However, we did not find such a correlation in our data set or meta-analyses when we considered only HBeAg-negative or HBeAg-positive patients, which is consistent with previous observations [36] . On the other hand, our observation of shorter half-life of infected cells in HBeAg-negative infection could contribute to the lower baseline viral load seen in these patients, because each infected cell should produce fewer virions over its shorter life span. This effect is in addition to lower viral productivity in HBeAg-negative infection versus HBeAg-positive infection, because a recent study found that the number of intrahepatic replicating HBV DNA molecules per covalently closed circular DNA was much lower in HBeAg-negative infection [37] .
In our meta-analysis we included all the extant studies with viral dynamic data. This suggests that we collected data generated by different groups, and with different treatment protocols, different assays, and different viral kinetics models. Because this variability could bias our results, we also repeated our comparisons of HBeAg-positive and HBeAg-negative infection using more homogeneous studies, including 2 studies conducted by us, with similar sampling and the same modeling method. Restricting the analyses in this way helps control for the effect of different studies. Crucially, in these more restricted analyses, we also reached the same conclusions (see also Lewin et al [38] ).
Cytoplasmic HBeAg can enter both the major histocompatibility complex (MHC) class I pathway and the MHC class II pathway, but HBcAg probably does not enter the class II pathway [39] . Therefore, hepatocytes producing HBeAg may be targeted for destruction through both CD8-positive and/or CD4-positive pathways. Moreover, hepatocytes expressing concomitantly HBcAg and HBeAg epitopes could present a better immune target for cytotoxic T-lymphocytes, compared with cells expressing only HBcAg epitopes [40, 41] . These observations suggest a stronger immune response in the context of HBeAgpositive infection. In contrast, secreted HBeAg has been suggested to have a tolerogenic function, down-regulating the immune response against HBV [12, 40, 42] . Thus, in HBeAg-negative infection, lack of this tolerogenic effect may lead to a stronger immune response against the virus. What can the present study say about these mutually exclusive propositions? Although exact mechanisms remain unknown, our findings of faster clearance of virions and infected cells are compatible with a stronger immune response in the setting of HBeAg-negative infection. This indicates that the loss of the immunomodulatory functions of the secreted e protein has a dominating effect over any additional immune response it may elicit.
In conclusion, analysis of HBeAg-negative early viral kinetics under various antiviral treatments showed faster dynamics of HBV DNA and infected hepatocytes in comparison with HBeAg-positive chronic infection. These results reveal the dual role played by the immune response in maintaining lower viral levels and inducing faster turnover of infected cells, the latter of which may be responsible for the more aggressive nature of HBeAg-negative infection.
